Edwards Lifesciences announced on June 3rd local time that it plans to sell its Critical Care business unit to Becton Dickinson & Co. for $4.2 billion in an all-cash deal, further strengthening its focus on structural heart device business. The deal is expected to be completed by the end of 2024. In April of this year, Edwards announced the split of its Critical Care Division, which develops and sells blood and cardiac monitoring systems for surgical and critical care environments.